Marja-Riitta Taskinen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5377028/publications.pdf

Version: 2024-02-01

475 papers	59,061 citations	2093 100 h-index	1152 229 g-index
504 all docs	504 docs citations	504 times ranked	44158 citing authors

#	Article	IF	Citations
1	Effects of PNPLA3 I148M on hepatic lipid and veryâ€lowâ€density lipoprotein metabolism in humans. Journal of Internal Medicine, 2022, 291, 218-223.	2.7	5
2	Apolipoprotein Câ€III predicts cardiovascular events and mortality in individuals with type 1 diabetes and albuminuria. Journal of Internal Medicine, 2022, 291, 338-349.	2.7	10
3	Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia. Nature Reviews Cardiology, 2022, 19, 577-592.	6.1	59
4	High-resolution population-specific recombination rates and their effect on phasing and genotype imputation. European Journal of Human Genetics, 2021, 29, 615-624.	1.4	17
5	An expanded analysis framework for multivariate GWAS connects inflammatory biomarkers to functional variants and disease. European Journal of Human Genetics, 2021, 29, 309-324.	1.4	19
6	Effects of Evolocumab on the Postprandial Kinetics of Apo (Apolipoprotein) B100- and B48-Containing Lipoproteins in Subjects With Type 2 Diabetes. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 962-975.	1.1	18
7	Effects of liraglutide on the metabolism of triglycerideâ€rich lipoproteins in type 2 diabetes. Diabetes, Obesity and Metabolism, 2021, 23, 1191-1201.	2.2	20
8	Relationship between de novo lipogenesis and serum sex hormone binding globulin in humans. Clinical Endocrinology, 2021, 95, 101-106.	1.2	11
9	Remnant cholesterol predicts progression of diabetic nephropathy and retinopathy in type 1 diabetes. Journal of Internal Medicine, 2021, 290, 632-645.	2.7	32
10	Relationship of low molecular weight fluorophore levels with clinical factors and fenofibrate effects in adults with type 2 diabetes. Scientific Reports, 2021, 11, 18708.	1.6	1
11	Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategiesâ€”a consensus statement from the European Atherosclerosis Society. European Heart Journal, 2021, 42, 4791-4806.	1.0	303
12	Metabolism of Triglyceride-Rich Lipoproteins. Handbook of Experimental Pharmacology, 2021, , 133-156.	0.9	6
13	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal, 2020, 41, 111-188.	1.0	4,871
14	Interaction of chylomicron remnants and VLDLs during ultracentrifuge separation based on the Svedberg flotation rate â€“ Authorsâ€™ response. Journal of Internal Medicine, 2020, 287, 118-118.	2.7	0
15	Apolipoprotein B48 metabolism in chylomicrons and very lowâ€density lipoproteins and its role in triglyceride transport in normoâ€and hypertriglyceridemic human subjects. Journal of Internal Medicine, 2020, 288, 422-438.	2.7	25
16	Impact of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab on the postprandial responses of triglyceride-rich lipoproteins in type II diabetic subjects. Journal of Clinical Lipidology, 2020, 14, 77-87.	0.6	26
17	A higher glycemic response to oral glucose is associated with higher plasma apolipoprotein C3 independently of BMI in healthy twins. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 459-466.	1.1	1
18	The dual glucoseâ€dependent insulinotropic peptide and glucagonâ€like peptideâ€1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2020, 22, 2451-2459.	2.2	83

#	Article	IF	Citations
19	Liver nucleotide biosynthesis is linked to protection from vascular complications in individuals with long-term type 1 diabetes. Scientific Reports, 2020, 10, 11561.	1.6	8
20	The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans. Frontiers in Endocrinology, 2020, 11, 474.	1.5	81
21	Causes and Consequences of Hypertriglyceridemia. Frontiers in Endocrinology, 2020, 11, 252.	1.5	122
22	Niacin Cures Systemic NAD+ Deficiency and Improves Muscle Performance in Adult-Onset Mitochondrial Myopathy. Cell Metabolism, 2020, 31, 1078-1090.e5.	7.2	154
23	Polygenic Hyperlipidemias and Coronary Artery Disease Risk. Circulation Genomic and Precision Medicine, 2020, 13, e002725.	1.6	60
24	Triglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumab. European Journal of Preventive Cardiology, 2020, 27, 1663-1674.	0.8	9
25	The acute effect of metabolic cofactor supplementation: a potential therapeutic strategy against nonâ€alcoholic fatty liver disease. Molecular Systems Biology, 2020, 16, e9495.	3.2	39
26	Uric acid predicts <scp>longâ€term</scp> cardiovascular risk in type 2 diabetes but does not mediate the benefits of fenofibrate: The <scp>FIELD</scp> study. Diabetes, Obesity and Metabolism, 2020, 22, 1388-1396.	2.2	6
27	Hepatic saturated fatty acid fraction is associated with de novo lipogenesis and hepatic insulin resistance. Nature Communications, 2020, 11, 1891.	5.8	63
28	Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal, 2020, 41, 2313-2330.	1.0	776
29	Effects of TM6SF2 E167K on hepatic lipid and very low-density lipoprotein metabolism in humans. JCI Insight, 2020, 5, .	2.3	38
30	Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A singleâ€centre randomized controlled study. Diabetes, Obesity and Metabolism, 2019, 21, 84-94.	2.2	78
31	Coronary Artery Disease Risk and Lipidomic Profiles Are Similar in Hyperlipidemias With Family History and Populationâ€Ascertained Hyperlipidemias. Journal of the American Heart Association, 2019, 8, e012415.	1.6	24
32	Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150Âmg doses. Journal of Clinical Lipidology, 2019, 13, 979-988.e10.	0.6	13
33	Dietary Fructose and the Metabolic Syndrome. Nutrients, 2019, 11, 1987.	1.7	152
34	2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis, 2019, 290, 140-205.	0.4	1,753
35	Genetic architecture of human plasma lipidome and its link to cardiovascular disease. Nature Communications, 2019, 10, 4329.	5.8	120
36	Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD. Current Atherosclerosis Reports, 2019, 21, 27.	2.0	72

#	Article	IF	Citations
37	The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMÎ±) paradigm: conceptual framework and therapeutic potential. Cardiovascular Diabetology, 2019, 18, 71.	2.7	104
38	Residual vascular risk in diabetes â€“ Will the SPPARM alpha concept hold the key?. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2019, 13, 2723-2725.	1.8	4
39	POLYGENIC HYPERLIPIDEMIAS AND CORONARY ARTERY DISEASE RISK. Journal of the American College of Cardiology, 2019, 73, 1690.	1.2	0
40	Investigation of human apoB48 metabolism using a new, integrated nonâ€steadyâ€state model of apoB48 and apoB100 kinetics. Journal of Internal Medicine, 2019, 285, 562-577.	2.7	37
41	Role of apolipoprotein Câ€III overproduction in diabetic dyslipidaemia. Diabetes, Obesity and Metabolism, 2019, 21, 1861-1870.	2.2	39
42	Crosstalk between nonalcoholic fatty liver disease and cardiometabolic syndrome. Obesity Reviews, 2019, 20, 599-611.	3.1	59
43	41-LB: Lipoprotein Subfractions Are Associated with Diabetic Microvascular Disease among 9,795 Patients in the FIELD Trial. Diabetes, 2019, 68, 41-LB.	0.3	0
44	22-LB: Baseline and Short-Term Change in Plasma Uric Acid on Fenofibrate Predict Cardiovascular Risk: A Post Hoc Analysis of FIELD. Diabetes, 2019, 68, 22-LB.	0.3	0
45	23-LB: Lipoprotein Subfractions Are Associated with Diabetic Cardiovascular Disease and Death among 9,795 Patients in the FIELD Trial. Diabetes, 2019, 68, .	0.3	1
46	An Integrated Understanding of the Rapid Metabolic Benefits of a Carbohydrate-Restricted Diet on Hepatic Steatosis in Humans. Cell Metabolism, 2018, 27, 559-571.e5.	7.2	321
47	Metabolic syndrome associates with left atrial dysfunction. Nutrition, Metabolism and Cardiovascular Diseases, 2018, 28, 727-734.	1.1	11
48	USF1 deficiency alleviates inflammation, enhances cholesterol efflux and prevents cholesterol accumulation in macrophages. Lipids in Health and Disease, 2018, 17, 285.	1.2	16
49	Characterization of different fat depots in NAFLD using inflammation-associated proteome, lipidome and metabolome. Scientific Reports, 2018, 8, 14200.	1.6	28
50	Efficacy and safety of alirocumab in individuals with type 2 diabetes mellitus with or without mixed dyslipidaemia: Analysis of the ODYSSEY LONG TERM trial. Atherosclerosis, 2018, 276, 124-130.	0.4	27
51	Kinetics of plasma triglycerides in abdominal obesity. Current Opinion in Lipidology, 2017, 28, 11-18.	1.2	60
52	Personal modelâ€assisted identification of NAD⁺ andÂglutathione metabolism as intervention target in NAFLD. Molecular Systems Biology, 2017, 13, 916.	3.2	147
53	Intestinal alkaline phosphatase at the crossroad of intestinal health and disease â€“ a putative role in type 1 diabetes. Journal of Internal Medicine, 2017, 281, 586-600.	2.7	44
54	Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal, 2017, 38, 2459-2472.	1.0	2,292

#	Article	IF	Citations
55	Adverse effects of fructose on cardiometabolic risk factors and hepatic lipid metabolism in subjects with abdominal obesity. Journal of Internal Medicine, 2017, 282, 187-201.	2.7	89
56	Baseline Circulating FGF21 Concentrations and Increase after Fenofibrate Treatment Predict More Rapid Glycemic Progression in Type 2 Diabetes: Results from the FIELD Study. Clinical Chemistry, 2017, 63, 1261-1270.	1.5	11
57	Fructose intervention for 12 weeks does not impair glycemic control or incretin hormone responses during oral glucose or mixed meal tests in obese men. Nutrition, Metabolism and Cardiovascular Diseases, 2017, 27, 534-542.	1.1	18
58	Family-specific aggregation of lipid GWAS variants confers the susceptibility to familial hypercholesterolemia in a large Austrian family. Atherosclerosis, 2017, 264, 58-66.	0.4	6
59	The Contribution of GWAS Loci in Familial Dyslipidemias. PLoS Genetics, 2016, 12, e1006078.	1.5	48
60	Minor Contribution of Endogenous GLP-1 and GLP-2 to Postprandial Lipemia in Obese Men. PLoS ONE, 2016, 11, e0145890.	1.1	19
61	Why Is Apolipoprotein CIII Emerging as a Novel Therapeutic Target to Reduce the Burden of Cardiovascular Disease?. Current Atherosclerosis Reports, 2016, 18, 59.	2.0	60
62	USF1 deficiency activates brown adipose tissue and improves cardiometabolic health. Science Translational Medicine, 2016, 8, 323ra13.	5.8	58
63	ApoA-II HDL Catabolism and Its Relationships With the Kinetics of ApoA-I HDL and of VLDL1, in Abdominal Obesity. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 1398-1406.	1.8	4
64	Biomarkers and prediction of myocardial triglyceride content in non-diabetic men. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 134-140.	1.1	5
65	Improved Estimation of Human Lipoprotein Kinetics with Mixed Effects Models. PLoS ONE, 2015, 10, e0138538.	1.1	4
66	Kinetic Studies to Elucidate Impaired Metabolism of Triglyceride-rich Lipoproteins in Humans. Frontiers in Physiology, 2015, 6, 342.	1.3	11
67	Kinetic and Related Determinants of Plasma Triglyceride Concentration in Abdominal Obesity. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 2218-2224.	1.1	58
68	Ectopic Fat Depots and Left Ventricular Function in Nondiabetic Men With Nonalcoholic Fatty Liver Disease. Circulation: Cardiovascular Imaging, 2015, 8, .	1.3	83
69	New insights into the pathophysiology of dyslipidemia in type 2 diabetes. Atherosclerosis, 2015, 239, 483-495.	0.4	314
70	Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 2015, 9, 65-71.	0.6	24
71	PPARÎ± gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis. Journal of Hepatology, 2015, 63, 164-173.	1.8	270
72	Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. European Heart Journal, 2015, 36, 2425-2437.	1.0	644

#	Article	IF	Citations
73	Relationship of fibroblast growth factor 21 with baseline and new on-study microvascular disease in the Fenofibrate Intervention and Event Lowering in Diabetes study. Diabetologia, 2015, 58, 2035-2044.	2.9	25
74	Paradoxical Dissociation Between Hepatic Fat Content and De Novo Lipogenesis Due to PNPLA3 Sequence Variant. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E821-E825.	1.8	64
75	The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study. Diabetologia, 2015, 58, 464-473.	2.9	78
76	High-fat meals induce systemic cytokine release without evidence of endotoxemia-mediated cytokine production from circulating monocytes or myeloid dendritic cells. Acta Diabetologica, 2015, 52, 315-322.	1.2	22
77	Measuring short-term liver metabolism non-invasively: postprandial and post-exercise 1H and 31P MR spectroscopy. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2015, 28, 57-66.	1.1	7
78	Factors associated with postprandial lipemia and apolipoprotein A-V levels in individuals with familial combined hyperlipidemia. BMC Endocrine Disorders, 2014, 14, 90.	0.9	10
79	Amerindian-specific regions under positive selection harbour new lipid variants in Latinos. Nature Communications, 2014, 5, 3983.	5.8	81
80	Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. European Heart Journal, 2014, 35, 2146-2157.	1.0	835
81	Hepatic lipogenesis and a marker of hepatic lipid oxidation, predict postprandial responses of triglycerideâ€rich lipoproteins. Obesity, 2014, 22, 1854-1859.	1.5	31
82	Interrelationships Between the Kinetics of VLDL Subspecies and HDL Catabolism in Abdominal Obesity: A Multicenter Tracer Kinetic Study. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 4281-4290.	1.8	22
83	Cardiac steatosis in patients with dilated cardiomyopathy. Heart, 2014, 100, 1107-1112.	1.2	28
84	Postprandial hypertriglyceridemia as a coronary risk factor. Clinica Chimica Acta, 2014, 431, 131-142.	0.5	157
85	Comment to the position paper on global recommendations for the management of dyslipidemia developed by the International Atherosclerosis Society (IAS). Atherosclerosis, 2014, 233, 508-509.	0.4	2
86	HDL-C and HDL-C/ApoA-I Predict Long-Term Progression of Glycemia in Established Type 2 Diabetes. Diabetes Care, 2014, 37, 2351-2358.	4.3	50
87	Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24week, double-blind, randomized Phase 3 trial. International Journal of Cardiology, 2014, 176, 55-61.	0.8	229
88	Patients with type 1 diabetes show signs of vascular dysfunction in response to multiple high-fat meals. Nutrition and Metabolism, 2014, 11, 28.	1.3	17
89	Different Lipid Variables Predict Incident Coronary Artery Disease in Patients With Type 1 Diabetes With or Without Diabetic Nephropathy: The FinnDiane Study. Diabetes Care, 2014, 37, 2374-2382.	4.3	24
90	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal, 2014, 35, 1824-1824.	1.0	16

#	Article	IF	Citations
91	Electrocardiographic changes associated with insulin resistance. Nutrition, Metabolism and Cardiovascular Diseases, 2014, 24, 315-320.	1.1	7
92	The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes and Endocrinology,the, 2014, 2, 655-666.	5.5	473
93	Linagliptin treatment in subjects with type 2 diabetes with and without mildâ€toâ€moderate renal impairment. Diabetes, Obesity and Metabolism, 2014, 16, 560-568.	2.2	43
94	A gene variant of PNPLA3, but not of APOC3, is associated with histological parameters of NAFLD in an obese population. Obesity, 2013, 21, 2138-2145.	1.5	57
95	A continuous-time adaptive particle filter for estimations under measurement time uncertainties with an application to a plasma-leucine mixed effects model. BMC Systems Biology, 2013, 7, 8.	3.0	4
96	Genomic study in Mexicans identifies a new locus for triglycerides and refines European lipid loci. Journal of Medical Genetics, 2013, 50, 298-308.	1.5	116
97	Cardiac steatosis and left ventricular function in men with metabolic syndrome. Journal of Cardiovascular Magnetic Resonance, 2013, 15, 103.	1.6	86
98	Acquired liver fat is a key determinant of serum lipid alterations in healthy monozygotic twins. Obesity, 2013, 21, 1815-1822.	1.5	6
99	Associations and interactions between lipid profiles, retinopathy and nephropathy in patients with type 1 diabetes: the <scp>F</scp>inn<scp>D</scp>iane <scp>S</scp>tudy. Journal of Internal Medicine, 2013, 274, 469-479.	2.7	26
100	Efficacy and safety of linagliptin in subjects with type 2 diabetes mellitus and poor glycemic control: Pooled analysis of data from three placebo-controlled phase III trials. Journal of Diabetes and Its Complications, 2013, 27, 274-279.	1.2	16
101	Diagnostic efficacy of myeloperoxidase to identify acute coronary syndrome in subjects with chest pain. Annals of Medicine, 2013, 45, 322-327.	1.5	8
102	1334 CORRELATION OF HUMAN LIVER PPAR GENE EXPRESSION WITH HISTOLOGICAL SEVERITY OF NASH AND ASSOCIATED METABOLIC DERANGEMENTS: RATIONALE FOR TARGETED THERAPY. Journal of Hepatology, 2013, 58, S538.	1.8	0
103	Deep subcutaneous adipose tissue is more saturated than superficial subcutaneous adipose tissue. International Journal of Obesity, 2013, 37, 620-622.	1.6	53
104	Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. European Heart Journal, 2013, 34, 3478-3490.	1.0	2,132
105	Cardiac Steatosis Associates With Visceral Obesity in Nondiabetic Obese Men. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 1189-1197.	1.8	98
106	Genomic, Transcriptomic, and Lipidomic Profiling Highlights the Role of Inflammation in Individuals With Low High-density Lipoprotein Cholesterol. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 847-857.	1.1	35
107	The effect of vildagliptin therapy on atherogenic postprandial remnant particles and <scp>LDL</scp> particle size in subjects with TypeÂ2 diabetes. Diabetic Medicine, 2013, 30, 756-757.	1.2	23
108	South African Dyslipidaemia Guideline Consensus Statement. South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care, 2013, 55, 9-18.	0.2	3

#	Article	IF	Citations
109	Ectopic lipid storage and insulin resistance: a harmful relationship. Journal of Internal Medicine, 2013, 274, 25-40.	2.7	183
110	Genetic Variation in SULF2 Is Associated with Postprandial Clearance of Triglyceride-Rich Remnant Particles and Triglyceride Levels in Healthy Subjects. PLoS ONE, 2013, 8, e79473.	1.1	28
111	Glycemic Control Over 5 Years in 4,900 People With Type 2 Diabetes. Diabetes Care, 2012, 35, 1165-1170.	4.3	33
112	Novel Loci for Metabolic Networks and Multi-Tissue Expression Studies Reveal Genes for Atherosclerosis. PLoS Genetics, 2012, 8, e1002907.	1.5	171
113	Transgenic Expression and Genetic Variation of Lmf1 Affect LPL Activity in Mice and Humans. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 1204-1210.	1.1	15
114	Decrease in circulating fibroblast growth factor 21 after an oral fat load is related to postprandial triglyceride-rich lipoproteins and liver fat. European Journal of Endocrinology, 2012, 166, 487-492.	1.9	32
115	Response Letter to D. Singhâ€Franco et al.. Diabetes, Obesity and Metabolism, 2012, 14, 1054-1055.	2.2	0
116	Management of Dyslipidemias in the Presence of the Metabolic Syndrome or Type 2 Diabetes. Current Cardiology Reports, 2012, 14, 721-731.	1.3	20
117	Statins are diabetogenic â€“ Myth or reality?. Atherosclerosis Supplements, 2012, 13, 1-10.	1.2	88
118	Postprandial accumulation of chylomicrons and chylomicron remnants is determined by the clearance capacity. Atherosclerosis, 2012, 222, 222-228.	0.4	52
119	South African Dyslipidaemia Guideline Consensus Statement:. Journal of Endocrinology Metabolism and Diabetes of South Africa, 2012, 17, 155-165.	0.4	30
120	Metabolomic analysis of polar metabolites in lipoprotein fractions identifies lipoprotein-specific metabolic profiles and their association with insulin resistance. Molecular BioSystems, 2012, 8, 2559.	2.9	12
121	Detailed metabolic and genetic characterization reveals new associations for 30 known lipid loci. Human Molecular Genetics, 2012, 21, 1444-1455.	1.4	89
122	Diabetes as a case study of chronic disease management with a personalized approach: The role of a structured feedback loop. Diabetes Research and Clinical Practice, 2012, 98, 5-10.	1.1	67
123	Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro. Journal of Hepatology, 2012, 57, 1276-1282.	1.8	232
124	Kinetic studies to investigate lipoprotein metabolism. Journal of Internal Medicine, 2012, 271, 166-173.	2.7	27
125	Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2â€ƒyears exposure in 24-week phase III trials followed by a 78-week open-label extension. International Journal of Clinical Practice, 2012, 66, 731-740.	0.8	36
126	Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study. Diabetologia, 2012, 55, 915-925.	2.9	80

#	Article	IF	Citations
127	Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. European Heart Journal, 2011, 32, 1345-1361.	1.0	993
128	ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European Heart Journal, 2011, 32, 1769-1818.	1.0	2,767
129	Macrophage cholesterol efflux to plasma and HDL in subjects with low and high homocysteine levels: A FIELD substudy. Atherosclerosis, 2011, 219, 259-265.	0.4	13
130	ESC/EAS Guidelines for the management of dyslipidaemias. Atherosclerosis, 2011, 217, 1-44.	0.4	180
131	ESC/EAS Guidelines for the management of dyslipidaemias. Atherosclerosis, 2011, 217, 3-46.	0.4	561
132	Dietary omega-3 polyunsaturated fatty acid intake is related to a protective high-density lipoprotein subspecies profile independent of genetic effects: A monozygotic twin pair study. Atherosclerosis, 2011, 219, 880-886.	0.4	19
133	839 SERUM APOLIPOPROTEIN CIII LEVELS DECLINE AFTER WEIGHT LOSS INDUCED IMPROVEMENT IN HEPATIC STEATOSIS. Journal of Hepatology, 2011, 54, S335-S336.	1.8	0
134	Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes, Obesity and Metabolism, 2011, 13, 65-74.	2.2	266
135	Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2011, 13, 374-377.	2.2	82
136	Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the field randomised trial. Cardiovascular Diabetology, 2011, 10, 102.	2.7	42
137	Heritability and familiality of type 2 diabetes and related quantitative traits in the Botnia Study. Diabetologia, 2011, 54, 2811-2819.	2.9	202
138	Longâ€TE ¹H MRS suggests that liver fat is more saturated than subcutaneous and visceral fat. NMR in Biomedicine, 2011, 24, 238-245.	1.6	62
139	Dual Metabolic Defects Are Required to Produce Hypertriglyceridemia in Obese Subjects. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 2144-2150.	1.1	133
140	Effects of Exenatide on Measures of Î²-Cell Function After 3 Years in Metformin-Treated Patients With Type 2 Diabetes. Diabetes Care, 2011, 34, 2041-2047.	4.3	221
141	Transcriptional Activation of Apolipoprotein CIII Expression by Glucose May Contribute to Diabetic Dyslipidemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 513-519.	1.1	129
142	A Genome-Wide Screen for Interactions Reveals a New Locus on 4p15 Modifying the Effect of Waist-to-Hip Ratio on Total Cholesterol. PLoS Genetics, 2011, 7, e1002333.	1.5	29
143	High Density Lipoprotein Structural Changes and Drug Response in Lipidomic Profiles following the Long-Term Fenofibrate Therapy in the FIELD Substudy. PLoS ONE, 2011, 6, e23589.	1.1	33
144	A family history of diabetes is associated with reduced physical fitness in the Prevalence, Prediction and Prevention of Diabetes (PPP)â€“Botnia study. Diabetologia, 2010, 53, 1709-1713.	2.9	71

#	Article	IF	Citations
145	Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes. Diabetologia, 2010, 53, 1846-1855.	2.9	67
146	A nonsynonymous SNP within PCDH15 is associated with lipid traits in familial combined hyperlipidemia. Human Genetics, 2010, 127, 83-89.	1.8	23
147	Increased apolipoprotein E level and reduced high-density lipoprotein mean particle size associate with low high-density lipoprotein cholesterol and features of metabolic syndrome. Metabolism: Clinical and Experimental, 2010, 59, 1502-1509.	1.5	18
148	Characterizing human adipose tissue lipids by long echo time ¹Hâ€MRS in vivo at 1.5â€‰Tesla: validation by gas chromatography. NMR in Biomedicine, 2010, 23, 466-472.	1.6	46
149	Optimization of N -methyl-N -[tert -butyldimethylsilyl]trifluoroacetamide as a derivatization agent for determining isotopic enrichment of glycerol in very-low density lipoproteins. Rapid Communications in Mass Spectrometry, 2010, 24, 586-592.	0.7	10
150	Exenatide Affects Circulating Cardiovascular Risk Biomarkers Independently of Changes in Body Composition. Diabetes Care, 2010, 33, 1734-1737.	4.3	139
151	Lipoprotein(a) as a cardiovascular risk factor: current status. European Heart Journal, 2010, 31, 2844-2853.	1.0	1,392
152	An Immune Response Network Associated with Blood Lipid Levels. PLoS Genetics, 2010, 6, e1001113.	1.5	112
153	Effects of Long-Term Fenofibrate Treatment on Markers of Renal Function in Type 2 Diabetes: The FIELD Helsinki substudy. Diabetes Care, 2010, 33, 215-220.	4.3	74
154	Composition and lipid spatial distribution of HDL particles in subjects with low and high HDL-cholesterol. Journal of Lipid Research, 2010, 51, 2341-2351.	2.0	111
155	Use of Genome-Wide Expression Data to Mine the â€œGray Zoneâ€•of GWA Studies Leads to Novel Candidate Obesity Genes. PLoS Genetics, 2010, 6, e1000976.	1.5	62
156	Reviewing statin therapy in diabetesâ€”Towards the best practise. Primary Care Diabetes, 2010, 4, 9-15.	0.9	13
157	PPARÎ±: an emerging therapeutic target in diabetic microvascular damage. Nature Reviews Endocrinology, 2010, 6, 454-463.	4.3	92
158	Introduction. Nutrition, Metabolism and Cardiovascular Diseases, 2010, 20, 377-378.	1.1	3
159	MS23 TARGETING ONLY HIGH LDL-CHOLESTEROL DOES NOT ELIMINATE RESIDUAL CARDIOVASCULAR RISK. Atherosclerosis Supplements, 2010, 11, 114.	1.2	0
160	MS49 THE HELSINKI FIELD SUBSTUDY: EFFECTS OF FENOFIBRATE AND HOMOCYSTEINE ON IN VITRO CHOLESTEROL EFFLUX POTENTIAL OF HDL AND PLASMA. Atherosclerosis Supplements, 2010, 11, 120.	1.2	0
161	Postprandial lipid and apolipoprotein responses following three consecutive meals associate with liver fat content in type 2 diabetes and the metabolic syndrome. Atherosclerosis, 2010, 211, 308-314.	0.4	28
162	One-year treatment with exenatide vs. Insulin Glargine: Effects on postprandial glycemia, lipid profiles, and oxidative stress. Atherosclerosis, 2010, 212, 223-229.	0.4	118

#	Article	IF	Citations
163	Abnormalities of triglyceride rich lipoproteins (TRLs) in type 2 diabetes and insulin resistance. ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2010, 22, 36-38.	0.4	1
164	Effect of HDL composition and particle size on the resistance of HDL to the oxidation. Lipids in Health and Disease, 2010, 9, 104.	1.2	44
165	Functional Variant Disrupts Insulin Induction of USF1. Circulation: Cardiovascular Genetics, 2009, 2, 522-529.	5.1	13
166	ApoCIII-Enriched LDL in Type 2 Diabetes Displays Altered Lipid Composition, Increased Susceptibility for Sphingomyelinase, and Increased Binding to Biglycan. Diabetes, 2009, 58, 2018-2026.	0.3	116
167	Galanin Preproprotein Is Associated With Elevated Plasma Triglycerides. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 147-152.	1.1	27
168	Serum, but not monocyte macrophage foam cells derived from low HDL-C subjects, displays reduced cholesterol efflux capacity. Journal of Lipid Research, 2009, 50, 183-192.	2.0	74
169	Novel LMF1 Nonsense Mutation in a Patient with Severe Hypertriglyceridemia. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 4584-4590.	1.8	52
170	ADAGIO-Lipids Gives Promises but Faces the Setbacks. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 339-340.	1.1	2
171	The ATF6-Met[67]Val Substitution Is Associated With Increased Plasma Cholesterol Levels. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 1322-1327.	1.1	21
172	Genetic Variation at the Proprotein Convertase Subtilisin/Kexin Type 5 Gene Modulates High-Density Lipoprotein Cholesterol Levels. Circulation: Cardiovascular Genetics, 2009, 2, 467-475.	5.1	33
173	Relationships of HDL Cholesterol, ApoA-I, and ApoA-II With Homocysteine and Creatinine in Patients With Type 2 Diabetes Treated With Fenofibrate. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 950-955.	1.1	59
174	Role of insulin as a negative regulator of plasma endocannabinoid levels in obese and nonobese subjects. European Journal of Endocrinology, 2009, 161, 715-722.	1.9	100
175	PRESS echo time behavior of triglyceride resonances at 1.5T: Detecting Ï‰-3 fatty acids in adipose tissue in vivo. Journal of Magnetic Resonance, 2009, 201, 39-47.	1.2	31
176	OSBPL10, a novel candidate gene for high triglyceride trait in dyslipidemic Finnish subjects, regulates cellular lipid metabolism. Journal of Molecular Medicine, 2009, 87, 825-835.	1.7	50
177	Serum saturated fatty acids containing triacylglycerols are better markers of insulin resistance than total serum triacylglycerol concentrations. Diabetologia, 2009, 52, 684-690.	2.9	169
178	Lipid abnormalities predict progression of renal disease in patients with type 1 diabetes. Diabetologia, 2009, 52, 2522-2530.	2.9	65
179	One-Year Treatment With Exenatide Improves Î²-Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients. Diabetes Care, 2009, 32, 762-768.	4.3	354
180	Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome. Diabetes Care, 2009, 32, 493-498.	4.3	488

#	Article	IF	Citations
181	Estimation of VLDL, IDL, LDL, HDL₂, apoA-I, and apoB from the Friedewald inputsâ€"apoB and IDL, but not LDL, are associated with mortality in type 1 diabetes. Annals of Medicine, 2009, 41, 451-461.	1.5	36
182	HDL Subspecies in Young Adult Twins: Heritability and Impact of Overweight. Obesity, 2009, 17, 1208-1214.	1.5	34
183	USF1 gene variants contribute to metabolic traits in men in a longitudinal 32-year follow-up study. Diabetologia, 2008, 51, 464-472.	2.9	20
184	Fatty liver, insulin resistance, and dyslipidemia. Current Diabetes Reports, 2008, 8, 60-64.	1.7	115
185	ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition and increased susceptibility for sphingomyelinase. Chemistry and Physics of Lipids, 2008, 154, S13.	1.5	0
186	Reconsideration of hydrophobic lipid distributions in lipoprotein particles. Chemistry and Physics of Lipids, 2008, 155, 57-62.	1.5	48
187	WW-Domain-Containing Oxidoreductase Is Associated with Low Plasma HDL-C Levels. American Journal of Human Genetics, 2008, 83, 180-192.	2.6	54
188	Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nature Genetics, 2008, 40, 189-197.	9.4	1,286
189	Long-Term Effects of Fenofibrate on Carotid Intima-Media Thickness and Augmentation Index in Subjects With Type 2 Diabetes Mellitus. Journal of the American College of Cardiology, 2008, 52, 2190-2197.	1.2	66
190	Genetic prediction of the metabolic syndrome. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2008, 2, 245-252.	1.8	4
191	Apolipoprotein E polymorphism is associated with both carotid and coronary atherosclerosis in patients with coronary artery disease. Nutrition, Metabolism and Cardiovascular Diseases, 2008, 18, 271-277.	1.1	41
192	Overproduction of Very Lowâ€"Density Lipoproteins Is the Hallmark of the Dyslipidemia in the Metabolic Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 1225-1236.	1.1	639
193	Common Missense Variant in the Glucokinase Regulatory Protein Gene Is Associated With Increased Plasma Triglyceride and C-Reactive Protein but Lower Fasting Glucose Concentrations. Diabetes, 2008, 57, 3112-3121.	0.3	264
194	Postprandial triglyceride-rich lipoproteins in insulin resistance and Type 2 diabetes. Future Lipidology, 2008, 3, 531-543.	0.5	5
195	HDL subfraction distribution of paraoxonase-1 and its relevance to enzyme activity and resistance to oxidative stress. Journal of Lipid Research, 2008, 49, 1246-1253.	2.0	34
196	HDL Composition Predicts New-Onset Cardiovascular Disease in Patients With Type 1 Diabetes. Diabetes Care, 2007, 30, 2706-2707.	4.3	25
197	Exploring the lipoprotein composition using Bayesian regression on serum lipidomic profiles. Bioinformatics, 2007, 23, i519-i528.	1.8	22
198	Postprandial Lipemia Associates with Liver Fat Content. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 3052-3059.	1.8	70

#	Article	IF	Citations
199	Is Metabolic Syndrome the Main Threat to Human Health in the Twenty-First Century?. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 2275-2275.	1.1	17
200	The Increase of Apolipoprotein A-V During Postprandial Lipemia Parallels the Response of Triglyceride-Rich Lipoproteins in Type 2 Diabetes: No relationship between apoA-V and postheparin plasma lipolytic activity. Diabetes Care, 2007, 30, 2083-2085.	4.3	17
201	Common ABCA1 variants, HDL levels, and cellular cholesterol efflux in subjects with familial low HDL. Journal of Lipid Research, 2007, 48, 1409-1416.	2.0	27
202	The inherent accuracy of 1H NMR spectroscopy to quantify plasma lipoproteins is subclass dependent. Atherosclerosis, 2007, 190, 352-358.	0.4	51
203	Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet, The, 2007, 370, 1687-1697.	6.3	918
204	Genome-Wide Association Analysis Identifies Loci for Type 2 Diabetes and Triglyceride Levels. Science, 2007, 316, 1331-1336.	6.0	2,623
205	LB-PO-860 COMPREHENSIVE METABOLOMIC CHARACTERISATION OF LIPOPROTEIN FRACTIONS REVEALS DIFFERENTIAL LIPOPROTEIN-SPECIFIC REGULATION OF XENOBIOTIC AND PRO-INFLAMMATORY METABOLITES IN PATIENTS WITH METABOLIC SYNDROME. Atherosclerosis Supplements, 2007, 8, 230-231.	1.2	0
206	Insulin resistance as predictor of the angiographic severity and extent of coronary artery disease. Annals of Medicine, 2007, 39, 137-144.	1.5	17
207	Variation in GYS1 Interacts with Exercise and Gender to Predict Cardiovascular Mortality. PLoS ONE, 2007, 2, e285.	1.1	17
208	1H NMR metabonomics of plasma lipoprotein subclasses: elucidation of metabolic clustering by self-organising maps. NMR in Biomedicine, 2007, 20, 658-672.	1.6	36
209	TCF7L2 is associated with high serum triacylglycerol and differentially expressed in adipose tissue in families with familial combined hyperlipidaemia. Diabetologia, 2007, 51, 62-69.	2.9	48
210	Relationship between lipid profiles and kidney function in patients with type 1 diabetes. Diabetologia, 2007, 51, 12-20.	2.9	44
211	The role of PPAR-Î± agonists in the prevention of CVD in diabetes. Current Diabetes Reports, 2007, 7, 83-85.	1.7	0
212	Metabolic syndrome aggravates the increased endothelial activation and lowâ€grade inflammation in subjects with familial low HDL. Annals of Medicine, 2006, 38, 229-238.	1.5	24
213	The FIELD study â€“ Authors' reply. Lancet, The, 2006, 367, 1142-1143.	6.3	2
214	Association of Paraoxonase-1 Activity and Concentration With Angiographic Severity and Extent of Coronary Artery Disease. Journal of the American College of Cardiology, 2006, 47, 2429-2435.	1.2	77
215	Should we dismiss fibrates for the treatment of diabetic dyslipidaemia?. Nutrition, Metabolism and Cardiovascular Diseases, 2006, 16, 509-512.	1.1	5
216	Diabetic dyslipidaemia. Current Opinion in Lipidology, 2006, 17, 238-246.	1.2	143

#	Article	IF	Citations
217	The effect of sensitisation to insulin with pioglitazone on fasting and postprandial lipid metabolism, lipoprotein modification by lipases, and lipid transfer activities in type 2 diabetic patients. Diabetologia, 2006, 49, 527-537.	2.9	64
218	Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia, 2006, 49, 755-765.	2.9	570
219	Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia, 2006, 49, 2049-2057.	2.9	302
220	Association of Carotid Intima-Media Thickness With Angiographic Severity and Extent of Coronary Artery Disease. American Journal of Cardiology, 2006, 97, 624-629.	0.7	78
221	Cross-species analyses implicate Lipin 1 involvement in human glucose metabolism. Human Molecular Genetics, 2006, 15, 377-386.	1.4	97
222	ApoE Polymorphism Is Associated With C-Reactive Protein in Low-HDL Family Members and in Normolipidemic Subjects. Mediators of Inflammation, 2006, 2006, 1-5.	1.4	14
223	Blockade of oestrogen biosynthesis in peripubertal boys: effects on lipid metabolism, insulin sensitivity, and body composition. European Journal of Endocrinology, 2006, 155, 453-460.	1.9	46
224	Decreased High-Density Lipoprotein (HDL) Particle Size, Preî²-, and Large HDL Subspecies Concentration in Finnish Low-HDL Families. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 897-902.	1.1	69
225	Common Hepatic Nuclear Factor-4Â Variants Are Associated With High Serum Lipid Levels and the Metabolic Syndrome. Diabetes, 2006, 55, 1970-1977.	0.3	60
226	Serum Lipids and the Progression of Nephropathy in Type 1 Diabetes. Diabetes Care, 2006, 29, 317-322.	4.3	71
227	Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: Results from the Diabetes Atherosclerosis Intervention Study (DAIS). American Journal of Kidney Diseases, 2005, 45, 485-493.	2.1	231
228	No acute effect of nateglinide on postprandial lipid and lipoprotein responses in subjects at risk for type 2 diabetes. Diabetes/Metabolism Research and Reviews, 2005, 21, 376-381.	1.7	10
229	Alterations of lipids and apolipoprotein CIII in very low density lipoprotein subspecies in type 2 diabetes. Diabetologia, 2005, 48, 1207-1215.	2.9	72
230	Increased augmentation of central blood pressure is associated with increases in carotid intimaâ€“media thickness in type 2 diabetic patients. Diabetologia, 2005, 48, 1654-1662.	2.9	44
231	Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]. , 2005, 4, 13.		84
232	Overproduction of VLDL 1 Driven by Hyperglycemia Is a Dominant Feature of Diabetic Dyslipidemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 1697-1703.	1.1	235
233	Type 2 Diabetes as a Lipid Disorder. Current Molecular Medicine, 2005, 5, 297-308.	0.6	94
234	Insulin-Mediated Down-Regulation of Apolipoprotein A5 Gene Expression through the Phosphatidylinositol 3-Kinase Pathway: Role of Upstream Stimulatory Factor. Molecular and Cellular Biology, 2005, 25, 1537-1548.	1.1	88

#	Article	IF	Citations
235	USF1 and dyslipidemias: converging evidence for a functional intronic variant. Human Molecular Genetics, 2005, 14, 2595-2605.	1.4	78
236	Hypertriglyceridemia is associated with preÎ²-HDL concentrations in subjects with familial low HDL. Journal of Lipid Research, 2005, 46, 1643-1651.	2.0	28
237	A new combined multicompartmental model for apolipoprotein B-100 and triglyceride metabolism in VLDL subfractions. Journal of Lipid Research, 2005, 46, 58-67.	2.0	108
238	Metabolic Syndrome in Type 1 Diabetes: Association with diabetic nephropathy and glycemic control (the FinnDiane study). Diabetes Care, 2005, 28, 2019-2024.	4.3	360
239	Predictors of and Longitudinal Changes in Insulin Sensitivity and Secretion Preceding Onset of Type 2 Diabetes. Diabetes, 2005, 54, 166-174.	0.3	315
240	A male-specific quantitative trait locus on 1p21 controlling human stature. Journal of Medical Genetics, 2005, 42, 932-939.	1.5	19
241	Lifestyle modification improves risk factors in type 2 diabetes relatives. Diabetes Research and Clinical Practice, 2005, 68, 18-28.	1.1	36
242	APOA5 gene variants, lipoprotein particle distribution, and progression of coronary heart disease. Journal of Lipid Research, 2004, 45, 750-756.	2.0	103
243	Locus for quantitative HDL-cholesterol on chromosome 10q in Finnish families with dyslipidemia. Journal of Lipid Research, 2004, 45, 1876-1884.	2.0	22
244	Circulating Oxidized Low-Density Lipoprotein and Its Association With Carotid Intima-Media Thickness in Asymptomatic Members of Familial Combined Hyperlipidemia Families. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 1492-1497.	1.1	86
245	Active and low-active forms of serum phospholipid transfer protein in a normal Finnish population sample. Journal of Lipid Research, 2004, 45, 2303-2309.	2.0	36
246	What does postprandial hyperglycaemia mean?. Diabetic Medicine, 2004, 21, 208-213.	1.2	114
247	Low-grade inflammation, endothelial activation and carotid intima-media thickness in type 2 diabetes. Journal of Internal Medicine, 2004, 256, 119-127.	2.7	66
248	Familial combined hyperlipidemia is associated with upstream transcription factor 1 (USF1). Nature Genetics, 2004, 36, 371-376.	9.4	295
249	Tamoxifen treatment reverses the adverse effects of chemotherapy-induced ovarian failure on serum lipids. British Journal of Cancer, 2004, 91, 476-481.	2.9	19
250	Early alterations in the postprandial VLDL1 apoB-100 and apoB-48 metabolism in men with strong heredity for type 2 diabetes. Journal of Internal Medicine, 2004, 255, 273-279.	2.7	20
251	Lipoprotein metabolism in subjects with hepatic lipase deficiency. Metabolism: Clinical and Experimental, 2004, 53, 520-525.	1.5	15
252	Associations between HDL oxidation and paraoxonase-1 and paraoxonase-1 gene polymorphisms in families affected by familial combined hyperlipidemia. Nutrition, Metabolism and Cardiovascular Diseases, 2004, 14, 81-87.	1.1	8

#	Article	IF	Citations
253	Serum homocysteine concentrations, gemfibrozil treatment, and progression of coronary atherosclerosis. Atherosclerosis, 2004, 172, 267-272.	0.4	30
254	R643G polymorphism in PECAM-1 influences transendothelial migration of monocytes and is associated with progression of CHD and CHD events. Atherosclerosis, 2004, 177, 127-135.	0.4	42
255	Effects of a Mediterranean-inspired diet on blood lipids, vascular function and oxidative stress in healthy subjects. Clinical Science, 2004, 106, 519-525.	1.8	114
256	Diabetic dyslipidaemia: from basic research to clinical practice*. Diabetologia, 2003, 46, 733-749.	2.9	717
257	Low HDL cholesterol concentration is associated with increased intima-media thickness independent of arterial stiffness in healthy subjects from families with low HDL cholesterol. European Journal of Clinical Investigation, 2003, 33, 457-463.	1.7	26
258	Insulin resistance and adiposity correlate with acute-phase reaction and soluble cell adhesion molecules in type 2 diabetes. Atherosclerosis, 2003, 166, 387-394.	0.4	235
259	A novel functional polymorphism in the PECAM-1 gene (53G>A) is associated with progression of atherosclerosis in the LOCAT and REGRESS studies. Atherosclerosis, 2003, 168, 131-138.	0.4	36
260	LDL-cholesterol, HDL-cholesterol or triglyceridesâ€"which is the culprit?. Diabetes Research and Clinical Practice, 2003, 61, S19-S26.	1.1	46
261	Combined Analysis of Genome Scans of Dutch and Finnish Families Reveals a Susceptibility Locus for High-Density Lipoprotein Cholesterol on Chromosome 16q. American Journal of Human Genetics, 2003, 72, 903-917.	2.6	89
262	A novel cellular marker of insulin resistance and early atherosclerosis in humans is related to impaired fat cell differentiation and low adiponectin. FASEB Journal, 2003, 17, 1434-1440.	0.2	108
263	Circulating Adiponectin Levels Are Reduced in Nonobese but Insulin-Resistant First-Degree Relatives of Type 2 Diabetic Patients. Diabetes, 2003, 52, 1182-1186.	0.3	137
264	Progression of Atherosclerosis Is Associated With Variation in the Î±1-Antitrypsin Gene. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 644-649.	1.1	69
265	IGF Binding Protein-1 and Carotid Intima-Media Thickness in Type 2 Diabetes: Response to Conti et al.. Diabetes Care, 2003, 26, 1654-1655.	4.3	1
266	Determinants of low HDL levels in familial combined hyperlipidemia. Journal of Lipid Research, 2003, 44, 1536-1544.	2.0	29
267	Relationships Between Low-Density Lipoprotein Particle Size, Plasma Lipoproteins, and Progression of Coronary Artery Disease. Circulation, 2003, 107, 1733-1737.	1.6	263
268	Fat Distribution, Lipid Accumulation in the Liver, and Exercise Capacity Do Not Explain the Insulin Resistance in Healthy Males with a Family History for Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 4232-4238.	1.8	30
269	Fenofibrate Lowers Plasma Triglycerides and Increases LDL Particle Diameter in Subjects With Type 2 Diabetes. Diabetes Care, 2002, 25, 627-628.	4.3	43
270	Reduced IGFBP-1 Is Associated With Thickening of the Carotid Wall in Type 2 Diabetes. Diabetes Care, 2002, 25, 1807-1812.	4.3	33

#	Article	IF	Citations
271	Impaired Responsiveness to NO in Newly Diagnosed Patients With Rheumatoid Arthritis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 1637-1641.	1.1	198
272	Peroxisome Proliferator-Activated Receptor Î± Gene Variants Influence Progression of Coronary Atherosclerosis and Risk of Coronary Artery Disease. Circulation, 2002, 105, 1440-1445.	1.6	136
273	Susceptibility of LDL to oxidation in vitro and antioxidant capacity in familial combined hyperlipidemia: comparison of patients with different lipid phenotypes. Annals of Medicine, 2002, 34, 48-54.	1.5	18
274	Association Between Carotid Intima-Media Thickness and Low-Density Lipoprotein Size and Susceptibility of Low-Density Lipoprotein to Oxidation in Asymptomatic Members of Familial Combined Hyperlipidemia Families. Stroke, 2002, 33, 1255-1260.	1.0	59
275	Carotid artery intima-media thickness in Finnish families with familial combined hyperlipidemia. Atherosclerosis, 2002, 162, 171-178.	0.4	22
276	A candidate gene study in low HDL-cholesterol families provides evidence for the involvement of the APOA2 gene and the APOA1C3A4 gene cluster. Atherosclerosis, 2002, 164, 103-111.	0.4	17
277	A low high density lipoprotein (HDL) level is associated with carotid artery intima-media thickness in asymptomatic members of low HDL families. Atherosclerosis, 2002, 165, 309-316.	0.4	37
278	Diabetic dyslipidemia. Atherosclerosis Supplements, 2002, 3, 47-51.	1.2	166
279	C3, hormone-sensitive lipase, and peroxisome proliferator-activated receptor [gamma] expression in adipose tissue of familial combined hyperlipidemia patients. Metabolism: Clinical and Experimental, 2002, 51, 664-670.	1.5	13
280	Genome Scans Provide Evidence for Low-HDL-C Loci on Chromosomes 8q23, 16q24.1-24.2, and 20q13.11 in Finnish Families. American Journal of Human Genetics, 2002, 70, 1333-1340.	2.6	91
281	Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes. Diabetes/Metabolism Research and Reviews, 2002, 18, 484-490.	1.7	44
282	Family histories of Type II diabetes and hypertension predict intimaâ€“media thickness in patients with Type I diabetes. Diabetologia, 2002, 45, 711-718.	2.9	27
283	Genetic influences contributing to LDL particle size in familial combined hyperlipidaemia. European Journal of Human Genetics, 2002, 10, 547-552.	1.4	12
284	LDL particle size in familial combined hyperlipidemia: effects of serum lipids, lipoprotein-modifying enzymes, and lipid transfer proteins. Journal of Lipid Research, 2002, 43, 598-603.	2.0	49
285	Relationship of Phospholipid Transfer Protein Activity to HDL and Apolipoprotein B-Containing Lipoproteins in Subjects With and Without Type 1 Diabetes. Diabetes, 2002, 51, 3300-3305.	0.3	63
286	LDL particle size in familial combined hyperlipidemia: effects of serum lipids, lipoprotein-modifying enzymes, and lipid transfer proteins. Journal of Lipid Research, 2002, 43, 598-603.	2.0	43
287	Cardiovascular Morbidity and Mortality Associated With the Metabolic Syndrome. Diabetes Care, 2001, 24, 683-689.	4.3	4,086
288	Effects of Oral and Transdermal Estrogen Replacement Therapy on Markers of Coagulation, Fibrinolysis, Inflammation and Serum Lipids and Lipoproteins in Postmenopausal Women. Thrombosis and Haemostasis, 2001, 85, 619-625.	1.8	242

#	Article	IF	Citations
289	Determinants of the severity and extent of coronary artery disease in patients with type-2 diabetes and in nondiabetic subjects. Coronary Artery Disease, 2001, 12, 99-106.	0.3	23
290	The metabolic syndrome influences the risk of chronic complications in patients with Type II diabetes. Diabetologia, 2001, 44, 1148-1154.	2.9	213
291	Metabolic effects of metformin in patients with impaired glucose tolerance. Diabetic Medicine, 2001, 18, 578-583.	1.2	51
292	Serum C3 but Not Plasma Acylation-Stimulating Protein Is Elevated in Finnish Patients With Familial Combined Hyperlipidemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 838-843.	1.1	37
293	Differing Associations of Lipid and Lipoprotein Disturbances With the Macrovascular and Microvascular Complications of Type 1 Diabetes. Diabetes Care, 2001, 24, 2071-2077.	4.3	74
294	Pathogenesis of dyslipidemia in type 2 diabetes. Experimental and Clinical Endocrinology and Diabetes, 2001, 109, S180-S188.	0.6	46
295	Angiographic severity and extent of coronary artery disease in patients with type 1 diabetes mellitus. American Journal of Cardiology, 2000, 86, 1080-1085.	0.7	75
296	Differences in HDL-cholesterol:apoA-I + apoA-II ratio and apoE phenotype with albuminuric status in Type I diabetic patients. Diabetologia, 2000, 43, 1353-1359.	2.9	24
297	Fibrinolytic Proteins and Progression of Coronary Artery Disease in Relation to Gemfibrozil Therapy. Thrombosis and Haemostasis, 2000, 83, 397-403.	1.8	17
298	Suppression of nocturnal fatty acid concentrations by bedtime carbohydrate supplement in type 2 diabetes: effects on insulin sensitivity, lipids, and glycemic control. American Journal of Clinical Nutrition, 2000, 71, 1108-1114.	2.2	16
299	Endothelial Dysfunction in Men With Small LDL Particles. Circulation, 2000, 102, 716-721.	1.6	120
300	Differential Effects of Oral and Transdermal Estrogen Replacement Therapy on Endothelial Function in Postmenopausal Women. Circulation, 2000, 102, 2687-2693.	1.6	107
301	G-250A Substitution in Promoter of Hepatic Lipase Gene Is Associated With Dyslipidemia and Insulin Resistance in Healthy Control Subjects and in Members of Families With Familial Combined Hyperlipidemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 1789-1795.	1.1	70
302	A nine-month, placebo-controlled study of the effects of growth hormone treatment on lipoproteins and LDL size in abdominally obese men. Growth Hormone and IGF Research, 2000, 10, 118-126.	0.5	16
303	A Genome-wide scan for low HDL-Cholesterol in genetically isolated finnish families with premature coronary heart disease. Atherosclerosis, 2000, 151, 236.	0.4	0
304	Reduced hormone-sensitive lipase activity is not a major metabolic defect in Finnish FCHL families. Atherosclerosis, 2000, 153, 373-381.	0.4	17
305	Postprandial metabolism of apolipoprotein B-48- and B-100-containing particles in type 2 diabetes mellitus: relations to angiographically verified severity of coronary artery disease. Atherosclerosis, 2000, 150, 167-177.	0.4	121
306	Evidence of linkage in familial combined hyperlipidemia to chromosome 1q21-q23. , 2000, , 56-58.		0

#	Article	IF	Citations
307	A marathon run increases the susceptibility of LDL to oxidation in vitro and modifies plasma antioxidants. American Journal of Physiology - Endocrinology and Metabolism, 1999, 276, E1083-E1091.	1.8	46
308	The Effect of Insulin Delivery Route on Lipoproteins in Type I Diabetic Patients on CAPD. Peritoneal Dialysis International, 1999, 19, 148-153.	1.1	21
309	Treatment of Obese Subjects with the Oral Growth Hormone Secretagogue MK-677 Affects Serum Concentrations of Several Lipoproteins, But Not Lipoprotein(a)1. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 2028-2033.	1.8	15
310	Coronary Flow Reserve in Young Men With Familial Combined Hyperlipidemia. Circulation, 1999, 99, 1678-1684.	1.6	98
311	Strategies for the Management of Diabetic Dyslipidaemia. Drugs, 1999, 58, 47-51.	4.9	16
312	Genomewide Scan for Familial Combined Hyperlipidemia Genes in Finnish Families, Suggesting Multiple Susceptibility Loci Influencing Triglyceride, Cholesterol, and Apolipoprotein B Levels. American Journal of Human Genetics, 1999, 64, 1453-1463.	2.6	137
313	Intense physical training decreases circulating antioxidants and endothelium-dependent vasodilatation in vivo. Atherosclerosis, 1999, 145, 341-349.	0.4	159
314	Effect of heparin-stimulated plasma lipolytic activity on VLDL APO B subclass metabolism in normal subjects. Atherosclerosis, 1999, 146, 381-390.	0.4	30
315	Constantly low HDL-cholesterol concentration relates to endothelial dysfunction and increased in vivo LDL-oxidation in healthy young men. Atherosclerosis, 1999, 147, 133-138.	0.4	131
316	Dyslipidemia in insulin resistance: A silent villain?. Atherosclerosis, 1999, 144, 12-13.	0.4	0
317	Endothelial dysfunction and insulin resistance in men with small LDL particles. Atherosclerosis, 1999, 144, 58-59.	0.4	0
318	Delayed clearance of postprandial large VLDL particles in normolipidemic carriers of LPL Asn291Ser mutation. Atherosclerosis, 1999, 144, 89.	0.4	0
319	Isolated low HDL-cholesterol syndrome in finnish families with premature CAD. Atherosclerosis, 1999, 144, 106.	0.4	0
320	New aspects to the pathophysiology of diabetic dyslipidemia. Atherosclerosis, 1999, 144, 153-154.	0.4	0
321	Postprandial Hypertriglyceridemia and Insulin Resistance in Normoglycemic First-Degree Relatives of Patients with Type 2 Diabetes. Annals of Internal Medicine, 1999, 131, 27.	2.0	118
322	Delayed clearance of postprandial large TG-rich particles in normolipidemic carriers of LPL Asn291Ser gene variant. Journal of Lipid Research, 1999, 40, 1663-1670.	2.0	33
323	Linkage of familial combined hyperlipidaemia to chromosome 1q21â€“q23. Nature Genetics, 1998, 18, 369-373.	9.4	241
324	Broader metabolic control in diabetes management. Diabetes/metabolism Reviews, 1998, 14, S39-S43.	0.2	0

#	Article	IF	Citations
325	Effects of dietary cholesterol on plasma lipoproteins and their subclasses in IDDM patients. Diabetologia, 1998, 41, 193-200.	2.9	20
326	Aggregation of dimyristoylphosphatidylglycerol liposomes by human plasma low density lipoprotein. Biochimica Et Biophysica Acta - Biomembranes, 1998, 1373, 147-162.	1.4	23
327	Postprandial responses of plasma lipids and lipoproteins in subjects with apoA-I(Lys107â†'0). Atherosclerosis, 1998, 137, 37-47.	0.4	3
328	Oestrogen replacement therapy and coronary heart disease. Annals of Medicine, 1998, 30, 443-451.	1.5	12
329	Genetic variation in the amino-terminal part of apolipoprotein B: studies in hyperlipidemic patients. Atherosclerosis, 1998, 138, 367-374.	0.4	1
330	The 5A/6A polymorphism in the promoter of the stromelysin-1 (MMP-3) gene predicts progression of angiographically determined coronary artery disease in men in the LOCAT gemfibrozil study. Atherosclerosis, 1998, 139, 49-56.	0.4	96
331	Modulated serum activities and concentrations of paraoxonase in high density lipoprotein deficiency states. Atherosclerosis, 1998, 139, 77-82.	0.4	60
332	Postprandial lipid metabolism in diabetes. Atherosclerosis, 1998, 141, S53-S55.	0.4	59
333	Associations Between Lipoproteins and the Progression of Coronary and Vein-Graft Atherosclerosis in a Controlled Trial With Gemfibrozil in Men With Low Baseline Levels of HDL Cholesterol. Circulation, 1998, 98, 1993-1999.	1.6	72
334	Haplotypes of the ApoA-I/C-III/A-IV Gene Cluster and Familial Combined Hyperlipidemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 1810-1817.	1.1	28
335	Decreased postprandial high density lipoprotein cholesterol and apolipoproteins A-I and E in normolipidemic smoking men: relations with lipid transfer proteins and LCAT activities. Journal of Lipid Research, 1998, 39, 1493-1502.	2.0	48
336	Lipid metabolism: new approaches to old problems. Current Opinion in Lipidology, 1998, 9, 185-187.	1.2	0
337	Effect of Obesity on the Response to Insulin Therapy in Noninsulin-Dependent Diabetes Mellitus. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 4037-4043.	1.8	132
338	EDITORIAL COMMENT: New insights into the regulation of lipoprotein metabolism: studies in procaryocytes, eukaryocytes, rodents, pigs, and people. Current Opinion in Lipidology, 1997, 8, 127-130.	1.2	3
339	4.W23.5 Is insulin regulation of VLDL production defective in insulin resistance?. Atherosclerosis, 1997, 134, 292.	0.4	0
340	4.P.213 Asn291Ser mutation in LPL gene does not cause fat intolerance in normotriglyceridemic carriers. Atherosclerosis, 1997, 134, 340.	0.4	1
341	Heterozygous hepatic lipase deficiency, due to two missense mutations R186H and L334F, in the HL gene. Atherosclerosis, 1997, 128, 165-174.	0.4	25
342	The insulin resistance syndrome and postprandial lipid intolerance in smokers. Atherosclerosis, 1997, 129, 79-88.	0.4	140

#	Article	IF	Citations
343	Responses of HDL subclasses, Lp(A-I) and Lp(A-I:A-II) levels and lipolytic enzyme activities to continuous oral estrogenâ€“progestin and transdermal estrogen with cyclic progestin regimens in postmenopausal women. Atherosclerosis, 1997, 129, 249-259.	0.4	23
344	Serum complement and familial combined hyperlipidemia. Atherosclerosis, 1997, 129, 271-277.	0.4	28
345	Phenotype expression in familial combined hyperlipidemia. Atherosclerosis, 1997, 133, 245-253.	0.4	54
346	1.P.128 LDL subclasses in familial combined hyperlipidemia (FCHL). Atherosclerosis, 1997, 134, 43.	0.4	0
347	1.P.131 The occurrence of small dense low density lipoprotein particles in familial combined hyperlipidemia. Atherosclerosis, 1997, 134, 44.	0.4	0
348	1.P.260 Candidate gene analysis in familial combined hyperlipidemia. Atherosclerosis, 1997, 134, 71.	0.4	0
349	3.P.80 The susceptibility of LDL to oxidation is determined by LDL particle size in familial combined hyperlipidemia (FCHL) subjects. Atherosclerosis, 1997, 134, 215.	0.4	0
350	In Vivo Low Density Lipoprotein Oxidation Relates to Coronary Reactivity in Young Men. Journal of the American College of Cardiology, 1997, 30, 97-102.	1.2	98
351	In vivo metabolism of apo A-I and apo A-II in subjects with apo A-I(Lys107â†'0) associated with reduced HDL cholesterol and Lp(AI w AII) deficiency. Atherosclerosis, 1997, 128, 213-222.	0.4	14
352	Lipids and lipoproteins as coronary risk factors in non-insulin-dependent diabetes mellitus. Lancet, The, 1997, 350, S20-S23.	6.3	187
353	Postprandial Elevation of ApoB-48-Containing Triglyceride-Rich Particles and Retinyl Esters in Normolipemic Males Who Smoke. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 2096-2102.	1.1	58
354	Metabolic Basis of Hypotriglyceridemic Effects of Insulin in Normal Men. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 1454-1464.	1.1	167
355	Quantitative Comparison of Angiographic Characteristics of Coronary Artery Disease in Patients With Noninsulin-Dependent Diabetes Mellitus Compared With Matched Nondiabetic Control Subjects. American Journal of Cardiology, 1997, 80, 550-556.	0.7	60
356	A study to determine the response of coronary atherosclerosis to raising low high density lipoprotein cholesterol with a fibric-acid derivative in men after coronary bypass surgery. Contemporary Clinical Trials, 1997, 18, 93-119.	2.0	22
357	Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM. Diabetologia, 1997, 40, 454-462.	2.9	285
358	Smoking cessation improves insulin sensitivity in healthy middleâ€aged men. European Journal of Clinical Investigation, 1997, 27, 450-456.	1.7	133
359	The Asnâ€291â†'Ser and Serâ€477â†'Stop mutations of the lipoprotein lipase gene and their significance for lipid metabolism in patients with hypertriglyceridaemia. European Journal of Clinical Investigation, 1997, 27, 928-935.	1.7	25
360	Triglyceride is the major atherogenic lipid in NIDDM. , 1997, 13, 93-98.		26

#	Article	IF	Citations
361	No Evidence of Linkage Between Familial Combined Hyperlipidemia and Genes Encoding Lipolytic Enzymes in Finnish Families. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 841-850.	1.1	40
362	Subjects With ApoA-I(Lys ₁₀₇ â†'0) Exhibit Enhanced Fractional Catabolic Rate of ApoA-I in Lp(AI) and ApoA-II in Lp(AI With AII). Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 873-880.	1.1	28
363	Prevention of the Angiographic Progression of Coronary and Vein-Graft Atherosclerosis by Gemfibrozil After Coronary Bypass Surgery in Men With Low Levels of HDL Cholesterol. Circulation, 1997, 96, 2137-2143.	1.6	338
364	Cholesterol efflux from Fu5AH hepatoma cells induced by plasma of subjects with or without coronary artery disease and non-insulin-dependent diabetes: importance of LpA-I:A-II particles and phospholipid transfer protein. Atherosclerosis, 1996, 127, 245-253.	0.4	101
365	Effects of postmenopausal estrogen/progestin replacement therapy on LDL particles; comparison of transdermal and oral treatment regimens. Atherosclerosis, 1996, 122, 153-162.	0.4	34
366	Insulin increases plasma leptin concentrations in normal subjects and patients with NIDDM. Diabetologia, 1996, 39, 993-996.	2.9	14
367	Different effects of continuous oestrogen-progestin and transdermal oestrogen with cyclic progestin regimens on low-density lipoprotein subclasses. European Journal of Clinical Investigation, 1996, 26, 1125-1133.	1.7	19
368	Effect of Pancreas Transplantation on Free Fatty Acid Metabolism in Uremic IDDM Patients. Diabetes, 1996, 45, 354-360.	0.3	16
369	Metabolic Consequences of a Family History of NIDDM (The Botnia Study): Evidence for Sex-Specific Parental Effects. Diabetes, 1996, 45, 1585-1593.	0.3	342
370	Criteria for Metabolic Control and Intervention in Diabetes. Diabetes, 1996, 45, S120-S122.	0.3	11
371	New Insights into Lipid Metabolism in Non-insulin-dependent Diabetes Mellitus. Annals of Medicine, 1996, 28, 335-340.	1.5	47
372	Development and Evaluation of an ELISA Method for the Determination of Lipoprotein Lipase Mass Concentration â€" Comparison with a Commercial, One-Step Enzyme Immunoassay. Clinical Chemistry and Laboratory Medicine, 1996, 34, 547-53.	1.4	1
373	Multiple Lipoprotein Abnormalities in Type I Diabetic Patients With Renal Disease. Diabetes, 1996, 45, 974-979.	0.3	56
374	Regulation of low-density lipoprotein particle size distribution in NIDDM and coronary disease: importance of serum triglycerides. Diabetologia, 1996, 39, 453-461.	2.9	13
375	Hormone Replacement Therapy Lowers Plasma Lp(a) Concentrations. Arteriosclerosis, Thrombosis, and Vascular Biology, 1996, 16, 1215-1221.	1.1	60
376	Long-term Use of Nicotine Gum Is Associated With Hyperinsulinemia and Insulin Resistance. Circulation, 1996, 94, 878-881.	1.6	117
377	Gemfibrozil Increases Plasma Levels of Cholesterylester Transfer Protein (Cetp), But Lowers Cholesterylester Transfer in Hypertriglyceridemic Subjects. Medical Science Symposia Series, 1996, , 557-565.	0.0	0
378	Insulin resistance and lipoprotein metabolism. Current Opinion in Lipidology, 1995, 6, 153-160.	1.2	108

#	Article	IF	Citations
379	Effect of insulin treatment on serum lipoprotein(a) in non-insulin-dependent diabetes. European Journal of Clinical Investigation, 1995, 25, 194-200.	1.7	12
380	Lipid intolerance in smokers. Journal of Internal Medicine, 1995, 237, 449-455.	2.7	87
381	Postmenopausal hormone replacement therapy and plasma lipoproteins. Journal of Internal Medicine, 1995, 238, 385-387.	2.7	1
382	Effect of gemfibrozil on the regulation of HDL subfractions in hypertriglyceridaemic patients. Journal of Internal Medicine, 1995, 238, 429-436.	2.7	26
383	Decreasing triglyceride by gemfibrozil therapy does not affect the glucoregulatory or antilipolytic effect of insulin in nondiabetic subjects with mild hypertriglyceridemia. Metabolism: Clinical and Experimental, 1995, 44, 589-596.	1.5	39
384	LDL particle size in mildly hypertriglyceridemic subjects: no relation to insulin resistance or diabetes. Atherosclerosis, 1995, 113, 227-236.	0.4	39
385	Changes of lipolytic enzymes cluster with insulin resistance syndrome. Diabetologia, 1995, 38, 344-350.	2.9	11
386	Insulin resistance and abnormal albumin excretion in non-diabetic first-degree relatives of patients with NIDDM. Diabetologia, 1995, 38, 363-369.	2.9	12
387	ApoA-I _{Helsinki} (Lys ₁₀₇ â†'0) Associated With Reduced HDL Cholesterol and LpA-I:A-II Deficiency. Arteriosclerosis, Thrombosis, and Vascular Biology, 1995, 15, 1294-1306.	1.1	38
388	HDLs Containing Apolipoproteins A-I and A-II (LpA-I:A-II) as Markers of Coronary Artery Disease in Men With Nonâ€"Insulin- Dependent Diabetes Mellitus. Circulation, 1995, 92, 364-370.	1.6	55
389	Dyslipidemia in Niddm: New Insights. Medical Science Symposia Series, 1995, , 165-172.	0.0	0
390	Plasma Cholesteryl Ester Transfer Protein and Its Relationship to Plasma Lipoproteins and Apolipoprotein A-I-Containing Lipoproteins in IDDM Patients With Microalbuminuria and Clinical Nephropathy. Diabetes Care, 1994, 17, 412-419.	4.3	35
391	Comparison of Acute Daytime and Nocturnal Insulinization on Diurnal Glucose Homeostasis in NIDDM. Diabetes Care, 1994, 17, 805-809.	4.3	4
392	Normalization of Lipoprotein Composition by Intraperitoneal Insulin in IDDM: Role of increased hepatic lipase activity. Diabetes Care, 1994, 17, 6-12.	4.3	66
393	Plasma cholesteryl ester transfer protein activity in non-insulin-dependent diabetic patients with and without coronary artery disease. Metabolism: Clinical and Experimental, 1994, 43, 1498-1502.	1.5	32
394	Enrichment with apolipoprotein E characterizes postprandial TG-rich lipoproteins in patients with non-insulin-dependent diabetes mellitus and coronary artery disease: a preliminary report. Atherosclerosis, 1994, 105, 25-34.	0.4	26
395	Postprandial lipemia and lipoprotein lipase. Atherosclerosis, 1994, 109, 339-340.	0.4	0
396	Lipoprotein(a) in Type 1 Diabetic Patients with Renal Disease. Diabetic Medicine, 1994, 11, 961-967.	1.2	22

#	Article	IF	Citations
397	LDL subclasses in IDDM patients: relation to diabetic nephropathy. Diabetologia, 1994, 37, 681-688.	2.9	1
398	High density lipoprotein subfractions, apolipoprotein A-I containing lipoproteins, lipoprotein (a), and cholesteryl ester transfer protein activity in alcoholic women before and after ethanol withdrawal. European Journal of Clinical Investigation, 1993, 23, 406-417.	1.7	44
399	Changes in biological activity and immunoreactive mass of lipoprotein lipase in congenital nephrosis: relationship to hypertriglyceridaemia. European Journal of Clinical Investigation, 1993, 23, 368-374.	1.7	8
400	Effect of gemfibrozil on high density lipoprotein subspecies in non-insulin dependent diabetes mellitus. Relations to lipolytic enzymes and to the cholesteryl ester transfer protein activity. Atherosclerosis, 1993, 102, 79-89.	0.4	32
401	Effects of Gemfibrozil on Low-Density Lipoprotein Particle Size, Density Distribution, and Composition in Patients With Type II Diabetes. Diabetes Care, 1993, 16, 584-592.	4.3	78
402	Does Familial Hypertriglyceridemia Predispose to NIDDM?. Diabetes Care, 1993, 16, 1494-1501.	4.3	29
403	Metabolic Consequences of Sustained Suppression of Free Fatty Acids by Acipimox in Patients With NIDDM. Diabetes, 1993, 42, 1559-1566.	0.3	65
404	Regulation of Apolipoprotein A-I-Containing Lipoproteins in IDDM. Diabetes, 1993, 42, 1281-1288.	0.3	41
405	Different Acute and Chronic Effects of Acipimox Treatment on Glucose and Lipid Metabolism in Patients with Type 2 Diabetes. Diabetic Medicine, 1993, 10, 950-957.	1.2	30
406	Lipoproteins and Apoproteins in Diabetes. Frontiers in Diabetes, 1993, 12, 122-134.	0.4	3
407	Hyperinsulinism and Dyslipidemias as Coronary Heart Disease Risk Factors in NIDDM. Advances in Experimental Medicine and Biology, 1993, 334, 295-301.	0.8	15
408	Factors Influencing the Altered Lipoprotein System in Hypertriglyceridemia. Medical Science Symposia Series, 1993, , 467-475.	0.0	0
409	Seventy Years of Insulin: Where are We Now?. Annals of Medicine, 1992, 24, 231-232.	1.5	0
410	Comparison of Insulin Regimens in Patients with Non-Insulin-Dependent Diabetes Mellitus. New England Journal of Medicine, 1992, 327, 1426-1433.	13.9	330
411	Quantitative and Qualitative Lipoprotein Abnormalities in Diabetes Mellitus. Diabetes, 1992, 41, 12-17.	0.3	123
412	A novel polymorphism of apolipoprotein A-IV is the result of an asparagine to serine substitution at residue 127. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 1992, 1138, 27-33.	1.8	32
413	Effects of interferon alpha on insulin binding and glucose transport in human adipocytes. European Journal of Clinical Investigation, 1992, 22, 292-299.	1.7	11
414	Oneâ€year response to evening insulin therapy in nonâ€insulinâ€dependent diabetes. Journal of Internal Medicine, 1992, 231, 253-260.	2.7	10

#	Article	IF	Citations
415	The effect of moderate alcohol intake on serum apolipoprotein A-I-containing lipoproteins and lipoprotein (a). Metabolism: Clinical and Experimental, 1991, 40, 1168-1172.	1.5	80
416	Effects of continuous insulin infusion therapy on lipoprotein surface and core lipid composition in insulin-dependent diabetes mellitus. Metabolism: Clinical and Experimental, 1991, 40, 445-449.	1.5	42
417	Polymorphisms of the gene encoding cholesterol ester transfer protein and serum lipoprotein levels in subjects with and without coronary heart disease. Human Genetics, 1991, 87, 574-8.	1.8	59
418	Effect of Insulin Therapy on Metabolic Fate of Apolipoprotein B-Containing Lipoproteins in NIDDM. Diabetes, 1990, 39, 1017-1027.	0.3	112
419	3 Hyperlipidaemia in diabetes. Bailliere's Clinical Endocrinology and Metabolism, 1990, 4, 743-775.	1.0	95
420	Mechanisms behind the abnormalities of plasma lipids and lipoproteins in noninsulin-dependent diabetes. The Journal of Diabetic Complications, 1990, 4, 49-52.	0.2	0
421	Hypolipoproteinemia and Lipoprotein Lipase Deficiency. , 1990, , 381-394.		0
422	Bedtime Insulin for Suppression of Overnight Freeâ€“Fatty Acid, Blood Glucose, and Glucose Production in NIDDM. Diabetes, 1989, 38, 580-588.	0.3	66
423	Short-term effects of moderate alcohol consumption on lipid metabolism and energy balance in normal men. Metabolism: Clinical and Experimental, 1989, 38, 166-171.	1.5	78
424	Comparison of the effects of two different doses of alcohol on serum lipoproteins, HDL-subfractions and apolipoproteins A-I and A-II: a controlled study. European Journal of Clinical Investigation, 1988, 18, 472-480.	1.7	79
425	Effect of insulin treatment on fatty acids of plasma and erythrocyte membrane lipids in type 2 diabetes. Clinica Chimica Acta, 1988, 171, 293-303.	0.5	20
426	Effects of acipimox on serum lipids, lipoproteins and lipolytic enzymes in hypertriglyceridemia. Atherosclerosis, 1988, 69, 249-255.	0.4	47
427	I and c/g polymorphisms of the apolipoprotein B gene locus are associated with serum cholesterol and LDL-cholesterol levels in Finland. Atherosclerosis, 1988, 74, 47-54.	0.4	79
428	Elevated adipose tissue lipoprotein lipase activity in craniopharyngioma patients. Metabolism: Clinical and Experimental, 1988, 37, 418-421.	1.5	2
429	Changes in serum lipoprotein pattern induced by acute infections. Metabolism: Clinical and Experimental, 1988, 37, 859-865.	1.5	270
430	Effects of Endogenous Sex Steroids on Serum Lipoproteins and Postheparin Plasma Lipolytic Enzymes*. Journal of Clinical Endocrinology and Metabolism, 1988, 66, 408-413.	1.8	72
431	Lipoproteins, Lipolytic Enzymes, and Hormonal Status in Hypothyroid Women at Different Levels of Substitution*. Journal of Clinical Endocrinology and Metabolism, 1988, 66, 51-56.	1.8	80
432	Interrelationships Among Insulin's Antilipolytic and Glucoregulatory Effects and Plasma Triglycerides in Nondiabetic and Diabetic Patients With Endogenous Hypertriglyceridemia. Diabetes, 1988, 37, 1271-1278.	0.3	98

#	Article	IF	Citations
433	Short-Term Effects of Prednisone on Serum Lipids and High Density Lipoprotein Subfractions in Normolipidemic Healthy Men*. Journal of Clinical Endocrinology and Metabolism, 1988, 67, 291-299.	1.8	47
434	Basal and postprandial lipoprotein lipase activity in adipose tissue during caloric restriction and refeeding. Metabolism: Clinical and Experimental, 1987, 36, 625-630.	1.5	30
435	Alcohol-induced changes in serum lipoproteins and in their metabolism. American Heart Journal, 1987, 113, 458-464.	1.2	109
436	Coordination of very low-density lipoprotein triglyceride and apolipoprotein B metabolism in humans: Effects of obesity and non-insulin-dependent diabetes mellitus. American Heart Journal, 1987, 113, 522-526.	1.2	41
437	Plasma high-density lipoprotein concentration and subfraction distribution in relation to triglyceride metabolism. American Heart Journal, 1987, 113, 543-548.	1.2	100
438	7 Enzymes involved in triglyceride hydrolysis. Bailliere's Clinical Endocrinology and Metabolism, 1987, 1, 639-666.	1.0	66
439	Lipoprotein lipase in diabetes. Diabetes/metabolism Reviews, 1987, 3, 551-570.	0.2	214
440	Lipolytic Enzymes and HDL: Influence of Drugs and Hormones. Proceedings in Life Sciences, 1987, , 231-235.	0.5	0
441	Insulin resistance is a prominent feature of patients with pancreatogenic diabetes. Metabolism: Clinical and Experimental, 1986, 35, 718-727.	1.5	46
442	Increased Resting Metabolic Rates in Obese Subjects with Non-insulin-dependent Diabetes Mellitus and the Effect of Sulfonylurea Therapy. Diabetes, 1986, 35, 1-5.	0.3	103
443	Effects of NIDDM on Very-Low-Density Lipoprotein Triglyceride and Apolipoprotein B Metabolism: Studies Before and After Sulfonylurea Therapy. Diabetes, 1986, 35, 1268-1277.	0.3	157
444	Postheparin Plasma Lipoprotein and Hepatic Lipase Activities in Hyperinsulinemic Infants of Diabetic Mothers and in Large-for-Date Infants at Birth. Pediatric Research, 1986, 20, 623-627.	1.1	13
445	Postheparin Plasma Lipoprotein and Hepatic Lipase Activities in Hyperinsulinemic Infants of Diabetic Mothers and in Large-for-Date Infants at Birth. Pediatric Research, 1986, 20, 527-531.	1.1	7
446	Sequence of alcohol-induced initial changes in plasma lipoproteins (VLDL and HDL) and lipolytic enzymes in humans. Metabolism: Clinical and Experimental, 1985, 34, 112-119.	1.5	86
447	Effect of sulfonylurea therapy on plasma lipids and high-density lipoprotein composition in non-insulin-dependent diabetes mellitus. American Journal of Medicine, 1985, 79, 78-85.	0.6	40
448	Postheparin Plasma Lipase Activities and Plasma Lipoproteins in Newborn Infants. Pediatric Research, 1984, 18, 642-647.	1.1	15
449	Site of Insulin Resistance in Type 1 Diabetes: Insulin-Mediated Glucose Disposalin Vivoin Relation to Insulin Binding and Action in Adipocytesin Vitro*. Journal of Clinical Endocrinology and Metabolism, 1984, 59, 1183-1192.	1.8	51
450	Accelerated turnover of very low density lipoprotein triglycerides in chronic alcohol users. Atherosclerosis, 1984, 53, 185-193.	0.4	62

#	Article	IF	Citations
451	Plasma Lipoproteins, Lipolytic Enzymes, and Very Low Density Lipoprotein Triglyceride Turnover in Cushingâ€™s Syndrome*. Journal of Clinical Endocrinology and Metabolism, 1983, 57, 619-626.	1.8	109
452	No Evidence of Amyloidosis in Type I Diabetics Treated with Continuous Subcutaneous Insulin Infusion. Diabetes, 1983, 32, 88-90.	0.3	10
453	Role of hepatic endothelial lipase in the metabolism of plasma HDL2. Atherosclerosis, 1982, 44, 237-240.	0.4	12
454	In vitro catabolism of human plasma very low density lipoproteins. Atherosclerosis, 1982, 41, 381-394.	0.4	34
455	High density lipoprotein subfractions and postheparin plasma lipases in alcoholic men before and after ethanol withdrawal. Metabolism: Clinical and Experimental, 1982, 31, 1168-1174.	1.5	150
456	Human postheparin plasma hepatic lipase activity against triacylglycerol and phospholipid substrates. Clinica Chimica Acta, 1982, 122, 39-45.	0.5	22
457	Lipoprotein lipase activity of adipose tissue, skeletal muscle and post-heparin plasma in primary endogenous hypertriglyceridaemia: relation to lipoprotein pattern and to obesity. European Journal of Clinical Investigation, 1982, 12, 433-438.	1.7	24
458	High density lipoprotein subfractions in relation to lipoprotein lipase activity of tissues in manâ€”evidence for reciprocal regulation of HDL2 and HDL3 levels by lipoprotein lipase. Clinica Chimica Acta, 1981, 112, 325-332.	0.5	135
459	Lipoprotein lipase of adipose tissue and skeletal muscle in human obesity: Response to glucose and to semistarvation. Metabolism: Clinical and Experimental, 1981, 30, 810-817.	1.5	70
460	Effect of parenteral hyperalimentation on serum lipoproteins and on lipoprotein lipase activity of adipose tissue and skeletal muscle. European Journal of Clinical Investigation, 1981, 11, 317-323.	1.7	22
461	Lipoprotein lipase activity in adipose tissue and skeletal muscle of human diabetics during insulin deprivation and restoration. Scandinavian Journal of Clinical and Laboratory Investigation, 1981, 41, 263-268.	0.6	20
462	A micromethod for assay of lipoprotein lipase activity in needle biopsy samples of human adipose tissue and skeletal muscle. Clinica Chimica Acta, 1980, 104, 107-117.	0.5	91
463	Effects of caloric restriction on lipid metabolism in man changes of tissue lipoprotein lipase activities and of serum lipoproteins. Atherosclerosis, 1979, 32, 289-299.	0.4	79
464	Lipoprotein lipase activity in adipose tissue and skeletal muscle of runners: Relation to serum lipoproteins. Metabolism: Clinical and Experimental, 1978, 27, 1661-1671.	1.5	352
465	Relation of plasma high-density lipoprotein cholesterol to lipoprotein-lipase activity in adipose tissue and skeletal muscle of man. Atherosclerosis, 1978, 29, 497-501.	0.4	224
466	Effect of Acute Ethanol Load on Postheparin Plasma Lipoprotein Lipase and Hepatic Lipase Activities and Intravenous Fat Tolerance. Hormone and Metabolic Research, 1978, 10, 220-223.	0.7	26
467	Nocturnal Hypertriglyceridemia and Hyperinsulinemia Following Moderate Evening Intake of Alcohol. Acta Medica Scandinavica, 1977, 202, 173-177.	0.0	30
468	Lipoprotein Lipase Activity in Adipose Tissue and in Postheparin Plasma in Human Obesity. Acta Medica Scandinavica, 1977, 202, 399-408.	0.0	46

#	Article	IF	Citations
469	Ethanol-induced Alterations of Glucose Tolerance, Postglucose Hypoglycemia, and Insulin Secretion in Normal, Obese, and Diabetic Subjects. Diabetes, 1975, 24, 933-943.	0.3	78
470	Early Response of Plasma Insulin to Small Doses of Intravenous Glucose: Effect of Obesity. Journal of Clinical Endocrinology and Metabolism, 1974, 39, 418-424.	1.8	8
471	INSULIN DEFICIENCY ASSOCIATED WITH HYPOGLYCEMIA AND GOOD GLUCOSE TOLERANCE IN HYPOPITUITARISM. Acta Medica Scandinavica, 1974, 195, 435-439.	0.0	3
472	EFFECT OF DIPHENYLHYDANTOIN ON PLASMA-INSULIN IN INSULINOMA. Lancet, The, 1973, 301, 604-605.	6.3	12
473	GLUCOSE TOLERANCE AND PLASMA INSULIN IN MAN DURING ACUTE AND CHRONIC ADMINISTRATION OF NICOTINIC ACID. Acta Medica Scandinavica, 1969, 186, 247-253.	0.0	63
474	Effect of Muscular Exercise on Insulin Secretion. Diabetes, 1968, 17, 209-218.	0.3	35
475	Effect of Acute Elevation of Plasma Glycerol, Triglyceride and FFA Levels on Glucose Utilization and Plasma Insulin. Diabetes, 1968, 17, 76-82.	0.3	83